Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32

BACKGROUND: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Natl Cancer Inst
Egile Nagusiak: Goodwin, Pamela J., Parulekar, Wendy R., Gelmon, Karen A., Shepherd, Lois E., Ligibel, Jennifer A., Hershman, Dawn L., Rastogi, Priya, Mayer, Ingrid A., Hobday, Timothy J., Lemieux, Julie, Thompson, Alastair M., Pritchard, Kathleen I., Whelan, Timothy J., Mukherjee, Som D., Chalchal, Haji I., Oja, Conrad D., Tonkin, Katia S., Bernstein, Vanessa, Chen, Bingshu E., Stambolic, Vuk
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4565534/
https://ncbi.nlm.nih.gov/pubmed/25740979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djv006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak